A careful mix of quality instrumentation, business strategy, and expert help is bringing nanotechnology products to the marketplace.
There is still time to prepare your entry in the 51st Annual R&D 100 Awards...
Dynamic light scattering is increasingly important for determining nanoparticle size, but...
Advances in microscopy and fundamental science are closely intertwined. Without prior understanding of the basis for research, the tools of microscopy are useless. Without microscopy, an understanding of how materials, chemistry, or life behave(s) at the molecular and atomic level cannot be discovered.
Nanotechnology typically describes any material, device, or technology where feature sizes are smaller than 100 nanometers in dimension. However, this new and uncharted direction in research provides a large spark for new product and drug delivery development. To achieve these discoveries, scientists must rely on specialized instruments and materials to drive their experiments and analysis.
When not properly controlled or monitored, a scientific instrument is of little practical use. Developers of scientific instrumentation are aware of this, and invest considerable time and money ensuring that users can properly achieve the results promised by the instrument’s design parameters.
Bruker Corporation has coupled highly efficient interferometer technology and proprietary chemometric methods for automatic identification and imaging of chemical species present. The HI 90 hyperspectral imager rapidly detects molecules over a large field of regard (FOR) in seconds and provides both spatial and spectral analysis of the FOR.
A new architecture for Olympus' IX line gives users flexibility and optics module makers a new development platform. Invented in 1850, the inverted microscope has been a laboratory stalwart, giving researchers a direct and simple platform for optically viewing samples. The concept is simple: By fixing the sample stage and allowing the optics equipment to adjust, the user has more control over the object under analysis.
New technologies and changing attitudes about effective, efficient research impact the way laboratories are equipped.
As the laboratory construction industry struggles to recover, fume hood manufacturers jockey for better positions and products.
Sample preparation workflows for mass spectrometric analysis that involve proteolysis are often labor intensive, time consuming, and user dependent. Typical proteomic workflows require enzymatic digestion, solid phase extraction, drying, and resuspension before the reversed phase liquid chromatography-mass spectrometry (LC-MS) analysis.
Until now, life science researchers had a narrow set of expectations for automation systems. The main focus of laboratory automation providers has been to develop liquid handling systems for high-throughput workflows processing very large samples numbers, primarily in screening laboratories.
Systems biology holds tremendous promise for the future of science and medicine, but some have criticized the field's lack of practical solutions. Experts counsel patience, saying progress has been strong and is accelerating.
Global R&D spending is forecast to grow by 3.7%, or $53.7 billion in 2013 to $1.496 trillion, according to research by analysts at Battelle, Columbus, Ohio, and R&D Magazine, Rockaway, N.J. The largest share of this increase, $22.9 billion, is expected to come from China, which continues its decade-long annual double digit increases in R&D investments.
The watchword heading into 2013 is uncertainty, and the effect on the U.S. research and development enterprise is more unclear than ever. The current economic condition and uneasy prospects for the future combined with a federal government funding projection that could range anywhere from flat to significant declines have limited the prospects for 2013.
With significant fiscal debates ongoing, a detailed discussion of FY 2013 federal R&D funding would be of limited value at this time. Instead we highlight a few key issues and describe how the current budget will likely be developed. For an up-to-date analysis of federal R&D appropriations, we recommend the AAAS R&D Budget and Policy Program.
R&D is generally a long-term investment, building upon the results of previous years' expenditures, leading first to the generation of new knowledge through basic research and ultimately to products and services through applied research, development, and commercialization. These are considered to be functional impacts—benefits that occur as a function of the R&D's completion and often at a scale much larger than the original investment.
The amount of R&D funded by U.S. academia is forecast to increase by 2.1% in 2013 to $12.7 billion. The amount of R&D performed by U.S. academia (funded by all sources) is expected to increase by 0.4% to $66.6 billion. Both of these values generally are well below 3% or larger range in previous Global R&D Funding Forecasts.